Continuous demand for life-saving vaccines is the major factor leading to the growth of the travel vaccines market in the region. Vaccines are essential in providing immunity against infectious diseases. Success stories of eradicating smallpox and polio by vaccines inspired many researchers and manufacturing companies. In recent times, vaccines helped control and prevent COVID–19 to a large extent. Moreover, factors such as the growing population, the MEA travel underlying mutations of bacteria and virus, and the development of new threats that require rapid solutions are likely to boost the demand for vaccines and are expected to flourish the market growth during the forecast period.
Despite several manufacturing challenges, vaccine production increased significantly. Technological developments enabled researchers and manufacturing companies to offer potential changes in the formulation, production, and development of vaccines. Also, growing developments in the healthcare industries in developing countries triggered the development and production of vaccines. Such programs are likely to increase the production of vaccines and meet the never-ending demand for immunization in the future.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA travel vaccines market. The MEA travel vaccines market is expected to grow at a good CAGR during the forecast period.
MEA Travel Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Strategic insights for the Middle East and Africa Travel Vaccines provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the Middle East and Africa Travel Vaccines refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.Middle East and Africa Travel Vaccines Strategic Insights
Middle East and Africa Travel Vaccines Report Scope
Report Attribute
Details
Market size in 2021
US$ 120.13 Million
Market Size by 2028
US$ 167.76 Million
Global CAGR (2021 - 2028)
4.9%
Historical Data
2019-2020
Forecast period
2022-2028
Segments Covered
By Product
By Application
Regions and Countries Covered
Middle East and Africa
Market leaders and key company profiles
Middle East and Africa Travel Vaccines Regional Insights
The MEA travel vaccines market is segmented into product, application, and country. The MEA travel vaccines market, based on product, is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others. In 2021, others segment held the largest share of the market. The MEA travel vaccines market, based on application, is segmented into domestic travel and outbound travel. In 2021, the outbound travel segment held the largest share of the market. Based on country, the MEA travel vaccines market is segmented into Saudi Arabia, South Africa, UAE, and the Rest of the MEA.
Abbott; Bharat Biotech; GlaxoSmithKline plc; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; and Sanofi are among the leading companies in the travel vaccines market in the region.
The Middle East and Africa Travel Vaccines Market is valued at US$ 120.13 Million in 2021, it is projected to reach US$ 167.76 Million by 2028.
As per our report Middle East and Africa Travel Vaccines Market, the market size is valued at US$ 120.13 Million in 2021, projecting it to reach US$ 167.76 Million by 2028. This translates to a CAGR of approximately 4.9% during the forecast period.
The Middle East and Africa Travel Vaccines Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East and Africa Travel Vaccines Market report:
The Middle East and Africa Travel Vaccines Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East and Africa Travel Vaccines Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East and Africa Travel Vaccines Market value chain can benefit from the information contained in a comprehensive market report.